A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

NCT05685173 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non-Hodgkins Lymphoma (B-NHL)

Interventions

DRUG: Odronextamab
DRUG: REGN5837

Sponsor

Regeneron Pharmaceuticals